Adaptation of the Mini-Mental State Examination (MMSE) for the Reunion Island Population

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-31

Study Completion Date

2027-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Mini-Mental State Examination (MMSE) is the most widely used cognitive screening and monitoring test for neurocognitive disorders in current clinical practice. Its French version was published in 1998 by the GRECO group (MMSE-GRECO). However, some items of this French version are not adapted to local Reunionese particularities.

The main objective is to propose and validate the psychometric properties of an adapted version of the MMSE, to the Reunionese culture (MMSE-RUN) in a healthy population and in a sick population (Alzheimer's Disease and Vascular Cognitive Disorder), and to compare its performance with the MMSE-GRECO.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Concordance Between Mini-Mental Stats Examination (MMSE) and an Adapted Version of the MMSE in Reunion Island Population (MMS-Run)

NCT05858489

Neurocognitive Deficit

UNKNOWN

Psychometric Validation of the "Antillanisée" Version of the Mini Mental State Examination (MMSEa)

NCT03324711

Elderly Patients Cognitive Disorder Alzheimer Disease

TERMINATED NA

Creation of an Ecological Tool Assessing Episodic Memory in Geriatrics

NCT05668598

Memory Disorders Neurocognitive Disorders

RECRUITING NA

Validation of the Montreal Cognitive Assessment in Patients With Mild and Major Neurocognitive Disorder

NCT03581643

Alzheimer Disease Mild Cognitive Impairment

COMPLETED

Self-screening of Cognitive Impairment in Primary Care

NCT04019665

Cognition Disorder Alzheimer Disease

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The MMSE score was described in 1975 by an American psychiatrist. Due to its good psychometric properties and its quick and simple administration, it has become the most widely known and used screening and monitoring test for neurocognitive disorders. The MMSE have been translated and adapted for use in many languages and cultures worldwide. Its brevity, ease of use, and established psychometric properties have contributed to its widespread adoption in clinical practice and research settings for detecting cognitive impairment and monitoring cognitive changes over time.

It has been adapted into French (MMSE-GRECO), as well as to other cultures in Europe, Asia, and Africa. In the French overseas territories, a Polynesian and Caribbean version have been published.

In Reunion Island, no adapted version has been published yet. Nevertheless, an early identification of cognitive disorders with adapted screening tools is essential because three risk factors for cognitive vulnerability converge: (1) an aging population (increasing the risk of developing Alzheimer's disease) with (2) a lower level of education (decreasing cognitive resilience), and (3) a higher frequency of cardiovascular risk factors (hypertension, diabetes, dyslipidemia), increasing the frequency of vascular cognitive disorders.

The objective of this study is to propose an adapted version of the test for the Reunion Island population (MMSE-RUN) and to validate its psychometric properties within a cohort of healthy subjects and patients (Alzheimer's disease and/or vascular cognitive disorder).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer s Disease Vascular Cognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Arm (Healthy indivuduals)

MMSE-RUN and MMSE GRECO questionnaires

Group Type OTHER

MMSE-RUN and MMSE GRECO

Intervention Type DIAGNOSTIC_TEST

Each participant (control and Case) will complete MMSE-RUN and MMSE-GRECO.

Case Arm (Patients with Alzheimer's disease or vascular cognitive impairment)

MMSE-RUN and MMSE GRECO questionnaires

Group Type OTHER

MMSE-RUN and MMSE GRECO

Intervention Type DIAGNOSTIC_TEST

Each participant (control and Case) will complete MMSE-RUN and MMSE-GRECO.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MMSE-RUN and MMSE GRECO

Each participant (control and Case) will complete MMSE-RUN and MMSE-GRECO.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* For the healthy population : aged 60 to 89 years, residing in Reunion for more than 5 years, able to understand the test instructions, available for a one-hour interview, affiliated with a social security scheme, with informed consent.
* For the sick population : aged 60 to 89 years, residing in Reunion for more than 5 years, presenting probable or possible Alzheimer's disease and/or probable vascular cognitive disorder, able to understand the test instructions, available for a one-hour interview, affiliated with a social security scheme, with informed consent.

Exclusion Criteria

* For the healthy populationhistory of neurological pathology, neurodegenerative pathology with cognitive expression, refusing to participate in the study, under legal protection.
* For the sick population: acute unresolved medical decompensation or acute psychic decompensation, refusing to participate in the study, under legal protection.

Minimum Eligible Age

60 Years

Maximum Eligible Age

89 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes